Clinical Trial Update: Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib S-Malate in recurrent or metastatic endometrial cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenosquamous Carcinoma
• Endometrial Cancer
• Endometrial Clear Cell Adenocarcinoma
• Endometrial Mixed Cell Adenocarcinoma
• Endometrial Serous Adenocarcinoma
• Endometrioid Adenocarcinoma
• Uterine Corpus Carcinosarcoma

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-07-14